Federal Rescheduling and South Carolina’s Legal Framework
The potential federal rescheduling of cannabis from Schedule I to Schedule III under the Controlled Substances Act could significantly alter the landscape for medical cannabis access in South Carolina. This development is poised to trigger specific provisions within existing state law, compelling officials to reassess the classification of cannabis at the state level. State Senator Tom Davis (R), a long-time advocate for medical cannabis legislation, indicated to The Post and Courier that federal action would initiate a series of legal consequences in South Carolina that the General Assembly would be unable to disregard.
Specifically, South Carolina law mandates that if a substance is added, deleted, or rescheduled as a controlled substance under federal law or regulation, state officials must then reschedule the drug in the “appropriate schedule” under state law within 30 days. This provision establishes a direct link between federal and state drug classifications. Furthermore, the South Carolina Controlled Substances Therapeutic Research Act, enacted in 1980, already outlines a program enabling cancer and glaucoma patients to obtain medical cannabis through methods deemed appropriate by the state health commissioner, consistent with federal law. This Act also allows for a Review Advisory Board to expand participation to other disease groups, subject to medical data presentation and federal agency approval.
The office of Governor Henry McMaster (R) confirmed to The Post and Courier that South Carolina law will “require the State to mirror the new federal order” on marijuana rescheduling. Concurrently, the South Carolina Department of Public Health (DPH) has acknowledged awareness of the proposed federal rescheduling and is actively “assessing the impacts to DPH and the state of South Carolina.”
Legislative Efforts and Proposed Framework for Medical Cannabis Access
Senator Tom Davis has been a consistent proponent of legislative reform to establish a regulated pathway for medical cannabis access. His proposed legislation, the South Carolina Compassionate Care Act, aims to create a comprehensive, patient-centered framework. Davis described this model as featuring:
- Physician authorization on the front end.
- Licensed cultivation and processing in the middle.
- Pharmacist dispensing on the back end.
This framework is designed to support patients, help ensure product safety, and provide regulatory clarity for both the public and the healthcare community. The legislation would permit patients to acquire medical marijuana from “therapeutic cannabis pharmacies,” which would be licensed by the state Board of Pharmacy. Patients would require a doctor’s recommendation for qualifying conditions, including specific ailments, terminal illnesses, and chronic diseases where opioids are the standard of care.
Past Legislative Hurdles
Despite strong public support, earlier versions of Senator Davis’s medical cannabis measure have faced significant challenges in the South Carolina General Assembly. A version passed the Senate in the 2024 session but did not advance in the House. Similar efforts in 2022 and 2025 also encountered procedural obstacles. House Speaker Murrell Smith (R) has previously tempered expectations, citing insufficient support within the GOP caucus to advance such reforms through his chamber, despite the Senate’s approval of an earlier iteration of the bill.
Political and Public Sentiment
Public opinion in South Carolina overwhelmingly supports medical cannabis legalization. A 2024 poll indicated that 93 percent of Democrats, 74 percent of Republicans, and 84 percent of independents back the reform. Governor McMaster has previously stated that there is a “compelling” case for legalizing medical marijuana in the state, acknowledging the strong arguments from supporters, even while noting reservations from law enforcement agencies.
However, concerns persist among some lawmakers regarding the potential for medical cannabis legalization to lead to broader adult-use reform, the implications for pharmacists involved in dispensing, and the possibility of federal preemption of state programs. Senator Davis has characterized the stance of some within his own party on medical marijuana as an “intellectually lazy position that doesn’t even try to present medical facts as they currently exist,” underscoring the ongoing political division despite public and some executive support for expanded medical cannabis access.
Disclaimer: This article is for informational purposes only and does not constitute medical advice. Hemp Gazette does not provide medical recommendations, diagnoses, or treatment plans. Always consult a qualified healthcare practitioner before making any decisions regarding your health or any medical condition. Statements concerning the therapeutic uses of hemp, cannabis, or cannabinoid-derived products have not been evaluated by Australia’s Therapeutic Goods Administration (TGA). Medicinal cannabis products in Australia are accessed via prescription pathways under TGA regulation.
